| Neurofibrillary Tangles | |
|---|---|
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Frontotemporal Dementia](/diseases/ftd), [Primary Progressive Aphasia](/diseases/primary-progressive-aphasia), [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy), [Corticobasal Degeneration](/diseases/corticobasal-degeneration) |
| Primary Proteins | [Tau protein](/proteins/tau) (hyperphosphorylated) |
| Brain Regions Affected | [Entorhinal cortex](/brain-regions/entorhinal-cortex), [Hippocampus](/brain-regions/hippocampus), [Cortex](/brain-regions/cerebral-cortex), Brainstem nuclei |
| Pathology Type | Intraneuronal inclusion |
| Primary Species | Human, Mouse models |
Neurofibrillary tangles (NFTs) are hallmark intracellular inclusions composed of aggregated, hyperphosphorylated tau protein that accumulate within neurons in Alzheimer's disease (AD) and related neurodegenerative disorders[1]. First described by Alois Alzheimer in 1907 alongside amyloid plaques, NFTs represent one of the two principal neuropathological lesions defining Alzheimer's disease[2]. The presence and distribution of NFTs in the brain correlate strongly with cognitive decline in AD, forming the basis of Braak staging—a neuropathological grading system that tracks disease progression based on NFT distribution[3].
NFTs develop when normal, soluble tau protein undergoes pathological hyperphosphorylation, causing it to detach from microtubules and aggregate into insoluble paired helical filaments (PHFs) and straight filaments (SFs)[4]. This process disrupts microtubule stability, impairs axonal transport, and ultimately leads to neuronal death. The progression of NFT pathology follows a predictable pattern, beginning in the entorhinal cortex and hippocampus before spreading to isocortical areas, mirroring the clinical progression of memory impairment and cognitive decline in AD[5].
Tau is a microtubule-associated protein encoded by the MAPT gene located on chromosome 17q21, primarily expressed in neurons where it plays essential roles in microtubule stabilization and axonal transport[6]. The tau protein exists in six isoforms ranging from 352 to 441 amino acids, generated by alternative splicing of exons 2, 3, and 10. These isoforms differ in the number of repeat domains (three or four) in the microtubule-binding region, with the 3R and 4R tau isoforms showing distinct binding affinities for microtubules[7].
In its normal state, tau binds to microtubules through its repeat domains, promoting polymerization and stability. This interaction is dynamically regulated by phosphorylation at multiple serine, threonine, and tyrosine residues. Approximately 80 potential phosphorylation sites exist on tau, and the balance between kinases and phosphatases controls tau's functional state[8]. Key kinases implicated in tau phosphorylation include glycogen synthase kinase-3β (GSK-3β), cyclin-dependent kinase 5 (CDK5), protein kinase A (PKA), and calcium/calmodulin-dependent kinase II (CaMKII). The primary phosphatase responsible for tau dephosphorylation is protein phosphatase 2A (PP2A)[9].
In AD and related tauopathies, tau becomes abnormally hyperphosphorylated at multiple sites, transforming from a microtubule-stabilizing protein into a toxic, aggregation-prone entity[10]. This hyperphosphorylation reduces tau's affinity for microtubules, causing it to disassociate and accumulate in the cytosol. Hyperphosphorylated tau seeds the formation of oligomers, which then aggregate into larger structures including paired helical filaments (PHFs) and straight filaments (SFs)—the structural building blocks of NFTs[11].
Beyond hyperphosphorylation, tau in NFTs undergoes several other post-translational modifications that influence its aggregation and toxicity:
The transition from soluble tau to insoluble NFTs involves a nucleation-dependent polymerization process. Initially, hyperphosphorylated tau monomers undergo conformational changes that expose aggregation-prone regions, particularly the hexapeptide sequences 306VQIVYK311 and 378VQIINK383 in the repeat domains[17]. These sequences form the core of tau filaments and drive the stacking of tau molecules into β-sheet-rich structures.
The aggregation process follows these stages:
Electron microscopy reveals two major filament types in NFTs:
Cryo-electron microscopy (cryo-EM) studies have elucidated the atomic structure of tau filaments in AD, revealing that the core consists of residues 306-378 arranged in a double-horseshoe fold, with the two C-shaped protofilaments interacting along their entire length[20]. This structural understanding has opened new avenues for therapeutic intervention targeting tau aggregation.
NFTs follow a highly predictable pattern of spread through the brain, forming the basis of the Braak staging system described by Heiko and Eva Braak[21]. This staging correlates strongly with clinical symptoms and provides a framework for understanding disease progression:
| Stage | Region | Clinical Correlation |
|---|---|---|
| I-II | Transentorhinal (Braak I-II) | Clinically silent |
| III-IV | Limbic (Braak III-IV) | Mild cognitive impairment |
| V-VI | Isocortical (Braak V-VI) | Moderate to severe dementia |
The NFT spread follows connectivity patterns, suggesting prion-like propagation of pathology along neuronal circuits[22]. This spreading may involve:
Certain neuronal populations demonstrate particular vulnerability to NFT formation:
The relationship between NFTs and amyloid plaques has been central to Alzheimer's disease research. According to the amyloid cascade hypothesis, amyloid-β (Aβ) deposition initiates a cascade of events leading to tau pathology, synaptic loss, and cognitive decline[24]. Evidence supporting this relationship includes:
However, the precise mechanistic link between Aβ and tau remains incompletely understood. Proposed mechanisms include:
Recent research demonstrates that pathological tau can spread between neurons in a prion-like manner[28]. This spreading involves:
This mechanism explains the characteristic pattern of NFT spread and has significant therapeutic implications, as blocking tau propagation could potentially halt disease progression[29].
While NFTs are most closely associated with Alzheimer's disease, they also occur in other neurodegenerative disorders collectively termed tauopathies:
Tau normally stabilizes microtubules and regulates axonal transport. NFT formation disrupts these functions:
NFT formation correlates with neuronal loss, though the exact relationship remains debated. Proposed mechanisms include:
NFTs serve as both a diagnostic marker and therapeutic target in AD. Current biomarker approaches include:
Multiple therapeutic approaches targeting tau pathology are under development:
Transgenic mouse models expressing human tau mutations have provided crucial insights into NFT formation:
Key methods for studying NFTs include:
The quantification of NFTs in post-mortem brain tissue provides essential information for diagnosis and research. Several standardized assessment methods have been developed:
Clinical-pathological correlations demonstrate strong relationships between NFT burden and cognitive impairment. The " Braak stage correlates significantly with dementia severity, with patients at Braak stage V-VI showing the most severe cognitive deficits[58]. However, recent studies indicate that synaptic loss and soluble tau oligomer levels may be stronger predictors of cognitive decline than NFT count alone[59].
Multiple genetic factors influence susceptibility to tauopathy:
Recent advances have opened new avenues for understanding and treating tauopathies:
Neurofibrillary tangles represent a central pathological feature of Alzheimer's disease and related tauopathies. The formation of these intracellular inclusions from hyperphosphorylated tau protein disrupts neuronal function through multiple mechanisms, including microtubule destabilization, axonal transport impairment, and ultimately neuronal death. The predictable spread of NFTs through connected brain regions provides a framework for understanding disease progression and developing therapeutic interventions. As our understanding of tau pathology deepens—from the atomic structure of filaments to the mechanisms of interneuronal spread—new opportunities emerge for disease-modifying therapies targeting this critical pathological hallmark.
Grundke-Iqbal I, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proceedings of the National Academy of Sciences. 1986. ↩︎
Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche Medizin. 1907. ↩︎
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica. 1991. ↩︎
Kidd M. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature. 1963. ↩︎
Delacourte A, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology. 2002. ↩︎
Weingarten MD, et al. A protein factor essential for microtubule assembly. Proceedings of the National Academy of Sciences. 1975. ↩︎
Goedert M, et al. 'Multiple isoforms of human tau protein: cDNA cloning, expression and structural diversity'. Journal of Molecular Biology. 1989. ↩︎
Hanger DP, et al. 'Tau phosphorylation: a therapeutic target for tauopathies?'. Biochemical Society Transactions. 2007. ↩︎
Liu F, et al. Roles of protein phosphatases in Alzheimer disease. CNS Drugs. 2005. ↩︎
Alonso AC, et al. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proceedings of the National Academy of Sciences. 2001. ↩︎
Crowther RA. Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proceedings of the National Academy of Sciences. 1991. ↩︎
Morishima-Kawashima M, et al. Proline-directed and non-proline-directed phosphorylation of PHF-tau. Journal of Biological Chemistry. 1995. ↩︎
Cohen TJ, et al. The acetylation of tau inhibits its function and promotes pathological aggregation. Nature Communications. 2011. ↩︎
Gamblin TC, et al. 'Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer''s disease'. Proceedings of the National Academy of Sciences. 2003. ↩︎
Liu Y, et al. O-GlcNAcylation is an early modification in Alzheimer's disease. Journal of Neural Transmission. 2004. ↩︎
Dorval V, Fraser PE. 'SUMO on tau: aggregation and transcription'. Neurobiology of Aging. 2007. ↩︎
von Bergen M, et al. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)). Proceedings of the National Academy of Sciences. 2000. ↩︎
Wisniewski HM, et al. Ultrastructural studies of the neuritic (senile) plaque and the neurofibrillary tangle. Acta Neuropathologica. 1975. ↩︎
Crowther RA, Wischik CM. Image reconstruction of the Alzheimer paired helical filament. EMBO Journal. 1985. ↩︎
Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer's disease. Nature. 2017. ↩︎
Braak H, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathologica. 1996. ↩︎
Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013. ↩︎
Gómez-Isla T, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Annals of Neurology. 1997. ↩︎
Hardy JA, Higgins GA. 'Alzheimer''s disease: the amyloid cascade hypothesis'. Science. 1992. ↩︎
Thal DR, et al. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology. 2002. ↩︎
Götz J, et al. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils. Science. 2001. ↩︎
Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991. ↩︎
Frost B, et al. Prion-like behavior in tauopathies. Cell Cycle. 2009. ↩︎
Clavaguera F, et al. Brain homogenates from Alzheimer's disease induce tau aggregation in the brains of young mice. Neurodegenerative Diseases. 2015. ↩︎
Hauw JJ, et al. The NINCDS-ADRDA criteria for the diagnosis of progressive supranuclear palsy. Neurology. 1994. ↩︎
Dickson DW, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. Journal of Neuropathology & Experimental Neurology. 2002. ↩︎
Foster NL, et al. 'Frontotemporal dementia and parkinsonism linked to chromosome 17: consensus on clinical criteria'. Annals of Neurology. 1999. ↩︎
Pickering-Brown S, et al. The neuropathology and clinical phenotype of FTD with progranulin mutations. Acta Neuropathologica. 2006. ↩︎
McKee AC, et al. 'Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury'. Journal of Neuropathology & Experimental Neurology. 2009. ↩︎
Irwin DJ, et al. Neuropathologic substrates of Parkinson disease dementia. Annals of Neurology. 2012. ↩︎
Mandelkow E, Mandelkow EM. Tau in physiology and pathology. Nature Reviews Neuroscience. 2011. ↩︎
Resende R, et al. Endoplasmic reticulum stress occurs in association with neurofibrillary tangle formation in patients with Alzheimer disease. Neuropathology and Applied Neurobiology. 2009. ↩︎
Dumont M, Beal MF. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radical Biology and Medicine. 2011. ↩︎
Nixon RA. The role of autophagy in neurodegenerative disease. Nature Medicine. 2013. ↩︎
Blennow K, Zetterberg H. 'Biomarkers for Alzheimer''s disease: current status and prospects for the future'. Annals of Internal Medicine. 2018. ↩︎
Xia CF, et al. ^18F-AV-1451 binds to tauopathy in the temporal cortex. Brain. 2016. ↩︎
Zetterberg H. Blood-based biomarkers for Alzheimer's disease-an update. Journal of Neuroscience Methods. 2019. ↩︎
Wischik CM, et al. Tau aggregation inhibitor therapy for Alzheimer's disease. Expert Opinion on Therapeutic Patents. 2015. ↩︎
Martinez A, et al. GSK-3 inhibitors as therapeutic agents for Alzheimer's disease. Mini Reviews in Medicinal Chemistry. 2002. ↩︎
Vargas-Caballero M, et al. 'PP2A and Alzheimer''s disease: a therapeutic target'. Journal of Alzheimer's Disease. 2017. ↩︎
Sigurdsson EM. Tau immunotherapy. Neurodegenerative Diseases. 2016. ↩︎
Salminen A, et al. Ubiquitin-proteasome system and autophagy are key pathways in tau clearance as therapeutic strategies. Current Alzheimer Research. 2011. ↩︎
Calafate S, et al. Tau propagates along networks as a template to induce amyloid-β aggregation. Acta Neuropathologica. 2015. ↩︎
Allen B, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. Journal of Neuroscience. 2002. ↩︎
Santacruz K, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005. ↩︎
Oddo S, et al. 'Triple-transgenic model of Alzheimer''s disease with plaques and tangles: intracellular Aβ and synaptic dysfunction'. Neuron. 2003. ↩︎
Israel MA, et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature. 2012. ↩︎
Alafuzoff I, et al. 'Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium'. Acta Neuropathologica. 2009. ↩︎
Mirra SS, et al. 'The CERAD protocol: Part II. Standardization of diagnostic assessment'. Neurology. 1991. ↩︎
Gallyas F. Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphologica Academiae Scientiarum Hungaricae. 1971. ↩︎
Blank M, et al. Thioflavin S filters out non-specific fluorophores to reveal Alzheimer disease amyloid plaques. Journal of Histochemistry & Cytochemistry. 2010. ↩︎
West MJ, et al. 'The hippocampus in Alzheimer''s disease: receptor mapping and neuropathology'. Brain Research. 1991. ↩︎
Bancher C, et al. Neurofibrillary tangles and amyloid in the brains of non-demented individuals. Acta Neuropathologica. 1993. ↩︎
Koss DJ, et al. Soluble, hyperphosphorylated tau species initiate synaptic dysfunction. Brain. 2016. ↩︎
Hutton M, et al. Association of missense and 5'-splice-site mutations in tau with the inherited FTDP-17. Nature. 1998. ↩︎
Strittmatter WJ, et al. 'Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer''s disease'. Proceedings of the National Academy of Sciences. 1993. ↩︎
Baker M, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Human Molecular Genetics. 1999. ↩︎
Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. New England Journal of Medicine. 2013. ↩︎
Lasagna-Reeves CA, et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Scientific Reports. 2012. ↩︎
Morris M, et al. 'Tau post-translational modifications: dynamic regulators of neuronal function and dysfunction'. Nature Reviews Neuroscience. 2018. ↩︎
Luo W, et al. Microglial activation and tau pathology. Brain Research. 2015. ↩︎
Zhou J, et al. Network analysis of tau PET imaging and its relationship to Alzheimer's disease. Brain. 2018. ↩︎
Frisoni GB, et al. Precision medicine for Alzheimer's disease. Nature Reviews Neurology. 2020. ↩︎